Register Login
Register to leave comments
  • News bot May 5, 2026, 11:05 a.m.

    📋 VIRIDIAN THERAPEUTICS, INC.\DE (VRDN) - Financial Results

    Filing Date: 2026-05-05

    Accepted: 2026-05-05 07:05:07

    Event Type: Financial Results

    Event Details:

    VIRIDIAN THERAPEUTICS, INC.\DE (VRDN) Reports the reporting period Financial Results VIRIDIAN THERAPEUTICS, INC.\DE (VRDN) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 141
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 762181
      • “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline data from both of elegrobart’s pivotal REVEAL phase 3 clinical trials, and earlier programs are moving ahead as planned,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “With veligrotug’s PDUFA target date next month, we have hired and deployed our full field teams, readied commercial supply and supply chain infrastructure, and continue to engage physicians, payers, and key opinion leaders. We believe we are well
      • positioned to deliver a successful launch. With the positive topline data from REVEAL
      • 2, in active and chronic TED, respectively, we believe that subcutaneous elegrobart has the potential to be the simplest and most convenient treatment for TED.” Recent
        • anticipated in Q1 2027
        • anticipated in Q4 2026
        • expected in 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Selling General Administrative 38.68K 17.10K $21.58K +126.15%
    Loss From Operations 116.17K 93.87K $22.30K +23.76%
    Net Loss 104.90K 86.91K $17.99K +20.70%
    Cash Equivalents Marketable Securities 762.18K 874.65K $-112.47K -12.86%
    Other Assets 26.84K 24.77K $2.07K +8.36%
    Revenue 135.00 72.00 $63.00 +87.50%
    Selling, General & Administrative 38.68K 17.10K $21.58K +126.15%
    Loss from Operations 116.17K 93.87K $22.30K +23.76%
    Other Income, Net 11.27K 6.95K $4.31K +62.04%
    Net Loss 104.90K 86.91K $17.99K +20.70%
    Cash and Marketable Securities 762.18K 874.65K $-112.47K -12.86%
    Other Assets 26.84K 24.77K $2.07K +8.36%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: VIRIDIAN THERAPEUTICS, INC.\DE
    • Ticker Symbol: VRDN

Search

News categories